Semaglutide LoE in India

24 Pages

Semaglutide’s loss of exclusivity in India is positioned as a major inflection point for obesity and metabolic markets. The paper explains why India’s scale, manufacturing capability, and market dynamics create an opportunity that diverges from traditional genericization models. It contrasts historical LoE patterns with emerging paradigms, estimates market potential, and outlines strategic imperatives for both generics and innovators, concluding with a forward-looking blueprint for India’s global impact.

Join for free to read

Case Study Amway India

White Paper Telematics Ecosystem in India

Case Study Ansys + Ecocat India

Report State of Ecommerce in India

More from IQVIA

White Paper Uncovering Insights: Tapping into APAC’s Potential for Obesity…

White Paper Mind Matters: Shining the spotlight on Alzheimer’s Disease in…

Report U.S.–India Medicine Partnership

Case Study Predictive typing tool for segmenting hospital accounts in India

White Paper

Semaglutide LoE in India

Semaglutide LoE in India

You Might Also Like

More from IQVIA